

JOURNAL OF  
**Pediatric Ophthalmology  
& Strabismus®**

**SLACK®**

6906 Grove Road  
Thorofare, NJ 08086-9447

**Executive Editor**  
Mary L. Jennell, ELS

**Associate Editor**  
Robert J. Vadel

**Assistant Editor**  
Allan Schneider

**Peer Review Coordinators**  
Dawn Barber  
Sheryl L. Grace

**Executive Vice  
President/Group Publisher**  
Richard N. Roash

**Vice President, Publishing  
Operations**  
John C. Carter

**Editorial Director/Journals**  
Jennifer A. Kilpatrick, ELS

**Vice President,  
US Advertising**  
Wayne McCourt

**Sales Director  
Eyecare Division**  
Frank Cassera

**Advertising Sales  
Representative**  
Teresa Pollizzi

**Advertising Sales Coordinator**  
Rebecca D'Amant

**Classified/Recruitment  
Manager**  
Kelly Wark

**Classified/Recruitment Sales**  
Lori Muscarel

**Production Coordinator**  
Joanne Peterson

**Production Director**  
Christine Malin

**Circulation Manager**  
Lester J. Robeson, CCP

**Director of Education**  
Kim E. Davis, MA

(US) 848-1000  
Fax: (856) 853-5991  
e-mail: jfco@slackinc.com  
Internet: <http://www.slack-inc.com/jpos.htm>

**EDITORS**

**Rudolph S. Wagner, MD**  
*Newark, New Jersey*

**Leonard B. Nelson, MD, MBA**  
*Philadelphia, Pennsylvania*

**COLUMN EDITORS**

**ABSTRACTS**  
Scott E. Olitsky, MD

**E-CONSULTS**  
Mark Rutlum, MD  
Deborah Alcorn, MD

**EDITORIAL BOARD**

**Deborah Alcorn, MD**  
*Stanford, California*

**Miles I. Burke, MD**  
*Cincinnati, Ohio*

**Anthony R. Caputo, MD**  
*Newark, New Jersey*

**Michael Clarke, FRCOphth**  
*Newcastle upon Tyne, England*

**Earl R. Crouch, Jr, MD**  
*Norfolk, Virginia*

**Patrick DeRespinis, MD**  
*Sutton Island, New York*

**Caleb Gonzalez, MD**  
*New Haven, Connecticut*

**Malcolm Ing, MD**  
*Honolulu, Hawaii*

**Mohamad Jaafar, MD**  
*Washington, DC*

**Harold P. Koller, MD**  
*Philadelphia, Pennsylvania*

**Robert Lingua, MD**  
*Corona, California*

**J. Arch McNamara, MD**  
*Philadelphia, Pennsylvania*

**Norman Medow, MD**  
*New York, New York*

**Kenneth Noble, MD**  
*New York, New York*

**Michael O'Keefe, MD**  
*Dublin, Ireland*

**Scott Olitsky, MD**  
*Buffalo, New York*

**James Reynolds, MD**  
*Buffalo, New York*

**Renee Richards, MD**  
*New York, New York*

**Gary Rogers, MD**  
*Columbus, Ohio*

**Steven Rubin, MD**  
*Great Neck, New York*

**Mark Rutlum, MD**  
*Milwaukee, Wisconsin*

**Robert Schwartz, MD**  
*Turkey, California*

**Carol Shields, MD**  
*Philadelphia, Pennsylvania*

**Jerry A. Shields, MD**  
*Philadelphia, Pennsylvania*

**Mitchell Strominger, MD**  
*Brooklyn, New York*

**Michael Trese, MD**  
*Royal Oak, Michigan*

**David S. Walton, MD**  
*Boston, Massachusetts*

**Fred Wang, MD**  
*New York, New York*

**Gerald Zaidman, MD**  
*Valhalla, New York*

- 112 **Pseudo-Brown's Syndrome Secondary to a Growing  
Conjunctival Dermolipoma**  
*Heysem Kırıklı, MD; Sinan Tutulipinar, MD; Ali Sefik Sanaç, MD; and  
Sevgül Bulgıç, MD*
- 114 **Ocular Involvement in Siblings With Familial  
Mediterranean Fever**  
*Ahmet Akman, MD; Bırgül Varan, MD; Yüncü A. Akova, MD; and  
Pınar Aydın, MD, PhD*
- 117 **Rufous Albinism**  
*J.S. Mehta, MBBS; P. Good, PhD; D. Mahavaj, MBBS; L. Butler, FRCOphth;  
S. Bussey, FRCP; and J. O'Shea, FRCOphth*

## Departments

- 59 **Editorial**  
*Rudolph S. Wagner, MD*
- 61 **Letters to the Editor**
- 96 **CME Quiz**
- 98 **Eye to Eye**  
**Medial Rectus Muscle Laceration**  
*Pandey: Miles J. Burke, MD; Monte Del Manue, MD; and Patrick DeRospinis, MD*
- 120 **Abstracts**
- 122 **Information for Contributors**
- 124 **Classified Marketplace**

The *Journal of Pediatric Ophthalmology & Strabismus* (ISSN 0191-3013; Canadian BN-12875 0466 RT) is published bi-monthly by SLACK Incorporated, 6900 Grove Road, Thorofore, New Jersey 08068-6447. Printed in the USA.

Copyright © 2001 by SLACK Incorporated. All Rights Reserved. No part of this publication may be reproduced without the written consent of the Publisher. All requests to reprint or use material published herein should be addressed to Karen Lambertson, SLACK Incorporated, 6900 Grove Road, Thorofore, NJ 08068. For reprint orders and prices, contact Karen Lambertson at (856) 548-1000.

Subscription rates: Individual—\$119.00 for 1 year; \$189.00 for 2 years; \$249.00 for 3 years. Institutional—\$129.00 for 1 year; \$209.00 for 2 years; \$289.00 for 3 years. Outside the US add \$49.00 per year. Resident rate in the US: \$69.00 (a letter of certification indicating residency of the subscriber is required). New subscriptions will start with the next published issue. Single back issues are \$29.00. Payment must accompany order. Subscription requests should be addressed to the publisher (except Japan). In Japan, contact Woodbell Incorporated, 4-22-11, Kitakassi, Edogawaku, Tokyo 134, Japan.

Change of address: Notice should be sent to the publisher 6 weeks in advance of effective date. Include old and new addresses with zip codes. The publisher cannot accept responsibility for undelivered copies. POSTMASTER: Send Form 3547 to the *Journal of Pediatric Ophthalmology & Strabismus*, 6900 Grove Road, Thorofore, New Jersey 08068. Periodicals postage is paid at Thorofore, New Jersey 08068-6447 and additional mailing offices. The *Journal of Pediatric Ophthalmology & Strabismus* is listed in Index Medicus, Ocular Resources Review, Medline, Excerpta Medica, Current Contents/Ophthalmology, Sci-Search, and Research Alert.

The ideas and opinions expressed in the *Journal of Pediatric Ophthalmology & Strabismus* do not necessarily reflect those of the editors or the publisher.

SLACK Incorporated makes an effort to maintain accuracy; however, we cannot guarantee accuracy, but suggest that the readers consult the maker or manufacturer's instructions before using any products.

# Effect of Botulinum Toxin A Chemodenervation in Sensory Strabismus

Sueng Han Han, MD; Helen Lew, MD; Chang Woog Jeong, MD; and Jong Bok Lee, MD

## ABSTRACT

**Purpose:** To study the effect of botulinum toxin type A chemodenervation in sensory strabismus.

**Methods:** Twelve patients with sensory strabismus were treated with an injection of botulinum toxin type A (Botox; Allergan, Irvine, Calif). Botulinum toxin type A was diluted with 0.9% sodium chloride without preservative at a dose that ranged from 1.25-5 U. A Teflon-coated needle electrode was inserted into the medial rectus muscle in cases of esotropia and into the lateral rectus muscle in cases of exotropia. Four patients were treated with  $\geq 2$  injections of botulinum toxin type A. Changes in the angle of strabismus and related complications were followed for  $>6$  months postinjection.

**Results:** The mean deviation before injection was 33.8 prism diopters ( $\Delta$ ) and the mean corrective effect on the deviation was 72.8% after injection in patients with sensory strabismus. The final deviation in 9 patients was  $<10 \Delta$ . Complications were hypertropia in 3 (25%) patients and conjunctival hemorrhage in 1 (8.3%) patient.

**Conclusion:** Botulinum toxin type A is likely to prevent muscle contracture and affect muscle and neuronal tissues. This study on the effects of sensory strabismus with botulinum toxin type A injection suggests it has the potential to replace surgery or be used as an adjuvant therapy.

**Journal of Pediatric Ophthalmology and Strabismus 2001;38:68-71.**

## INTRODUCTION

After Scott<sup>1</sup> reported in 1973 that Oculinum was effective in treating extraocular paralysis in an animal model, strabismus treatment with botulinum toxin type A was first used clinically in 1978.

Initially, botulinum toxin type A chemodenervation was confined to the treatment of acute paralytic strabismus; however, recently, it has been used to treat many types of strabismus. In addition, botulinum toxin type A has been found to be effective in correcting small-angle deviations of  $<10$  prism diopters ( $\Delta$ ) to  $15 \Delta$ , conditions that might be considered too minute for surgical intervention, but are still bothersome to the patient.<sup>2</sup> Botulinum toxin type A also can be a useful alternative for patients in whom general or local anesthesia is contraindicated. Furthermore, it is known to be safe and without systemic complications when repeatedly injected at

From the Department of Ophthalmology, Institute of Vision Research, Yonsei University College of Medicine, Seoul, Korea.

Originally submitted January 26, 2000.

Accepted for publication June 28, 2000.

Reprint requests: Sueng Han Han, MD, Dept of Ophthalmology, Yonsei University College of Medicine, Yonsei Medical Center Hospital, 146-92 In-gyeo-dong, Kangnam-Ku, Seoul, Korea.

TABLE  
PATIENTS WITH SENSORY STRABISMUS TREATED WITH BOTULINUM TOXIN TYPE A

Patient No./ Sex/Age (y)	Initial Deviation ( $\Delta$ )	Muscle Injected	No. Injections (U)	Follow-Up (mos)	Final Deviation ( $\Delta$ )
1/F/29	20, left exotropia	Left lateral rectus	1 (2.5)	7	10, left exotropia
2/F/32	35, right exotropia 14, right hypertropia	Right lateral rectus	1 (2.5)	8	8, right exotropia 4, right hypertropia
3/M/20	25, left exotropia	Left lateral rectus	1 (2.5)	6	Straight
4/F/46	25, right exotropia 10, right hypertropia	Right lateral rectus	1 (2.5)	6	6, right exotropia 6, right hypertropia
5/F/23	36, left esotropia	Left medial rectus	1 (2.5)	6	6, left esotropia 6, left hypertropia
6/M/28	45, left exotropia	Left lateral rectus	1 (2.5)	8	30, left exotropia
7/M/29	50, right exotropia	Right lateral rectus	1 (2.5)	6	25, right exotropia
8/F/52	50, right esotropia	Right medial rectus	2 (5.0, 2.5)	7	30, right esotropia
9/M/51	10, left exotropia 18, left hypotropia	Left lateral rectus	1 (1.25)	6	18, left hypotropia
10/F/21	50, left exotropia 15, left hypertropia	Left lateral rectus	3 (2.5, 2.5, 2.5)	6	8, left exotropia 15, left hypertropia
11/F/42	35, right esotropia	Right medial rectus	2 (1.25, 1.25)	6	6, right esotropia
12/M/26	30, right exotropia	Right lateral rectus	4 (2.5, 2.5, 2.5, 2.5)	8	4, right hypertropia

short intervals under topical anesthesia.<sup>2</sup> However, clinical experience is not comprehensive and the follow-up data are not extensive. This article reports the effects of botulinum toxin type A chemodenervation, which is believed to be a reversible treatment in sensory strabismus.

## MATERIALS AND METHODS

From January 1996 to December 1998, 12 patients (5 men and 7 women) with sensory strabismus were treated with botulinum toxin type A (Botox; Allergan, Irvine, Calif). Average patient age was 34.1 years (range: 21-52 years) (Table).

Three patients underwent strabismus surgery. All patients underwent complete ophthalmologic and orthoptic evaluation including duction testing, Hirschberg test, and modified Krinsky test. The conjunctival surface was anesthetized with four or five repeated instillations of 0.5% proparacaine at 1- or 2-minute intervals. A 27-gauge, 1.5", Teflon-coated, monopolar electrode needle and ground electrode were connected to an electromyographic amplifier. Each patient was directed to look away from the field of action of the injected muscle, and then, without conjunctival incision, the needle electrode was placed in the insertion site of the muscle.

The patient was asked to slowly look toward the field of action of the injected muscle. The needle was inserted along the muscle 25-30 mm posteriorly until a loud crackling noise was heard and the fluid was then injected. Botulinum toxin type A was diluted with 0.9% sodium chloride without preservative in a dose ranging from 1.25-5 U. The needle was inserted into the medial rectus muscle in cases of esotropia and into the lateral rectus muscle in cases of exotropia. Four patients were treated with  $\geq 2$  injections of botulinum toxin type A. Changes in the angle of strabismus and complications of botulinum toxin type A were followed for  $> 6$  months after last injection. Data were analyzed with the Statistical Analysis System (SAS) program, and the statistical method used was the Wilcoxon rank sum test.

## RESULTS

Mean deviation angle before injection was 33.8  $\Delta$  and 10.8  $\Delta$  at 6 months postinjection. The mean deviation correction achieved was 23  $\Delta$  (72.8%) and the final deviation in 9 patients was  $< 10 \Delta$ . In three cases, in which the patients underwent a subsequent surgery, the mean corrected deviation was 74.3%. In the remaining patients, the mean corrected deviation was 72.7%. However, there was no

statistically significant difference ( $P=.852$ ) between these groups. In 3 patients, residual horizontal deviations  $>10^\circ$  were noted after 6 months of follow-up. These patients refused additional injections or surgery (Table).

Complications included hypertropia in 3 (25%) patients and conjunctival hemorrhage in 1 (8.3%) patient. Complications of hypertropia were noted in 3 patients. In 1 patient, the deviation disappeared after 6 months of follow-up (Table). In the remaining 2 patients (patients 5 and 12), the amount of residual hypertropias after 6 months of follow-up was within  $10^\circ$ , and the patients showed no discomfort; therefore, surgical intervention was not undertaken. The commonly reported complication of proptosis did not occur and no systemic complications were observed.

## DISCUSSION

The seven antigenically distinct forms of botulinum neurotoxin (type A to G) are produced by the bacterium *Clostridium botulinum*. Botulinum toxin type A is easily made in deep culture and has a high molecular weight of 900,000 d.<sup>3,4</sup> Botulinum toxin type A interrupts the release of acetylcholine from the nerve terminal, although it does not interrupt the storage of acetylcholine in vesicles.<sup>4</sup> The toxin acts progressively on the motor nerve terminal and causes the end-plate potential to approach an irreducible quantity. Botulinum toxin does not interrupt the transmission of the nerve impulse and does not influence any electrical excitement or transmission in either the nerves or muscles.<sup>3,4</sup>

Botulinum toxin acts for a long period as it attaches firmly to the muscle and is rarely absorbed systemically. While other toxins were found in the blood 25 days after oral administration, type A toxin is fixed to the peripheral nerve system and tissue and is not found in the circulatory system. In the toxin-hemagglutinin complex, 900,000 d did not pass through the intestinal wall after oral administration. It is known that complexes of 150,000 d are found in the vascular system. The probability of the toxin passing the blood-brain barrier is low. It has been reported that if a large amount of toxin is injected, a small amount is transferred to the central nervous system through the vascular system. Because the onset of botulinum toxin is slow, its onset with doses of  $1 \times 10^{-5}$  pg and

$1.6 \times 10^{-3}$  pg is 2 or 3 days after injection, and its peak effect is achieved 5 or 6 days postinjection.<sup>3,8</sup>

The basic concept of the botulinum toxin type A effect, in the case of nonparalytic strabismus, is that the injected muscle is weakened and stretched by the antagonist, which is contracted secondarily. As the neuromuscular block by botulinum toxin type A disappears, deviation of the eyeball decreases. The injection site in esotropia is the medial rectus muscle and the injection site in vertical deviation is the vertical muscle, but not the oblique muscle.<sup>5,7</sup> In paralytic strabismus, botulinum toxin type A is usually injected as an antagonist of the paralytic muscle. The antagonist muscle is weakened and stretched and the deviation corrected. Secondary deviation due to antagonist contracture in paralytic strabismus is prevented or decreased.<sup>8</sup> It was reported that since the parietic antagonist is stretched further, ocular deviation is orthophoric when extraocular muscle paresis has partially or completely recovered, allowing surgery to be performed more easily.<sup>5,7</sup>

Recent studies have shown that botulinum toxin type A may have a permanent therapeutic effect, and two theories have been proposed. The first is that botulinum neurotoxin type A inhibits  $Ca^{2+}$ -dependent  $K^+$ -evoked release of acetylcholine, noradrenaline, and dopamine from rat cerebrocortical synaptosomes, where cholinergic terminals were most susceptible. Interestingly, none of the conditions could reverse the toxin-induced blockade of evoked release, which led to the conclusion that toxin-sensitive components exist in all nerve terminals that are concerned with transmitter release.<sup>9</sup> The second theory is that persistent muscular atrophic change was acquired in adult monkey extraocular muscles by injection of botulinum toxin type A into muscle. Spencer et al<sup>10</sup> reported the injected muscle fibers appeared normal and the vascularity recovered in proportion to the decreased cross-sectional area of the muscle fibers. On the basis of these findings, one of the long-term consequences of botulinum toxin paralysis of the extraocular muscle may be a change in the length-tension and fatigue characteristics of the extraocular muscles.<sup>9,10</sup>

In horizontal strabismus, botulinum toxin type A injections reduce the deviation by approximately 65%. Single injection can be expected to reduce the deviation to  $<10^\circ$  in approximately 30%-35% of patients.<sup>2</sup> Most patients, however, require more

than one injection, with the average number of injections varying anywhere from 1.5 to 2, depending on the type of strabismus and the size of the original deviation.<sup>7,11,12</sup> In vertical strabismus, botulinum toxin type A reduced the deviation by an average of 17 Δ, resulting in 41% reduction. These patients received an average of 1.7 injections and underwent follow-up for at least 6 months.

In consecutive strabismus, deviation was corrected in 87% of patients who were overcorrected and in 40%-60% of patients who were undercorrected. It has been reported that in childhood strabismus, the success rate is 65% in exotropia and 45% in esotropia.<sup>7</sup> In sensory strabismus, we found the mean deviation before injection was 33.8 Δ and the mean deviation 6 months after injection was 10.8 Δ. Therefore, the mean correction of deviation was 23 Δ (72.8%) and the deviation of 9 patients was <10 Δ.

Side effects and complications associated with botulinum toxin type A injection into an extraocular muscle are scleral perforation, retrobulbar hemorrhage, Adie's pupil, conjunctival hemorrhage, and headache. Postinjection complications are ptosis, vertical strabismus, and diplopia. Patients complained of diplopia due to temporary palsy, but the diplopia disappeared when the effect of the toxin decreased.<sup>2,8,13,14</sup> Complications in our study were hypertropia in 3 (25%) patients and conjunctival hemorrhage in 1 (8.3%) patient. However, ptosis did not occur, and no systemic complications were observed.

## CONCLUSION

Botulinum toxin type A is used to prevent muscle contractures and produce permanent changes in muscle and nerve tissues. Botulinum toxin type A

chemodenervation is a safe, easy, and inexpensive alternative to surgery for the treatment of strabismus. In addition, we expect the clinical indications for botulinum toxin type A chemodenervation will be extended. This study on the effects of sensory strabismus with botulinum toxin type A injection suggests it has the potential to replace surgery or be used as an adjuvant therapy.

## REFERENCES

- Scott AB. Botulinum toxin injection into extraocular muscles as an alternative to strabismus surgery. *Ophthalmology*. 1980;87:1044-1049.
- Buckley EG. Chemodenervation of extraocular muscles. In: Tarsan W, ed. *Duane's Clinical Ophthalmology*. 3rd ed. Philadelphia, Pa: JB Lippincott Co; 1993:1-14.
- Osaka M, Kelenor JL. Botulinum A toxin (Oculinum) in ophthalmology. *Surv Ophthalmol*. 1991;36:28-46.
- Sellin LC. The pharmacological mechanism of botulism. *Trends Pharmacol Sci*. 1985;6:80-82.
- Hoffman RO, Helveston EM. Botulinum in the treatment of adult myofascial disorders. *Int Ophthalmol Clin*. 1986;26:261-270.
- Metc HS. Botulinum injections for strabismus. *J Pediatr Ophthalmol Strabismus*. 1984;21:199-201.
- Carmona JA, Gormoll M, Tigges J, Lerman S. Botulinum chemodenervation treatment of strabismus. *J Pediatr Ophthalmol Strabismus*. 1984;21:223-226.
- Rosenbaum AL. Management of acute and chronic nerve palsy. In: Jankovic J, ed. *Therapy With Botulinum Toxin*. 1st ed. New York, NY: Marcel Dekker Inc; 1984:387-394.
- Ashron AC, Dolly JO. Characterization of the inhibitory action of botulinum neurotoxin type A on the release of vesicular transmitters from rat cerebocortical synaptosomes. *J Neurochem*. 1989;50:1808-1816.
- Spencer RF, McNeer KW. Botulinum toxin paralysis of adult monkey extraocular muscle. Structural alterations in orbital, singly innervated muscle fibers. *Arch Ophthalmol*. 1987;105:1703-1711.
- Scott AB. Botulinum toxin treatment of strabismus. In: *Focal Point* 1989. Clinical Module for Ophthalmologists. San Francisco, Calif: American Academy of Ophthalmology; 1989:1-11.
- Biglan AW, Burnstone RA, Rogers CL, Saunders RA. Management of strabismus with botulinum A toxin. *Ophthalmology*. 1989;96:935-943.
- Buckley EG. Botulinum endotoxin and paralytic strabismus. *Histories of Ophthalmology*. 1995;23:52-59.
- Ing MB. Botulinum alignment for congenital esotropia. *Ophthalmology*. 1993;100:318-322.